Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, SS-31 improves mitochondrial bioenergetics, reduces oxidative stress, and shows protective effects in models of ischemia-reperfusion, neurodegeneration, and other mitochondrial disorders4637137.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, SS-31 is a mitochondria-targeted tetrapeptide, d-Arg-dimethylTyr-Lys-Phe-NH2, that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure, improving electron transport, and reducing ROS production4637137143.
FOXO4-DRI is amino acids long, whereas SS-31 is longer as it has a length of 4 amino acids. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset. SS-31 is made up of a sequence of Arginine, dimethylTyr, Lysine, Phenylalanine.
FOXO4-DRI
Intracellular target is the FOXO4–p53 protein–protein interaction interface; it does not signal via a traditional cell-surface receptor38
SS-31
FOXO4-DRI
FOXO4
SS-31
Not assigned in the current dataset.
No related articles are linked to these peptides yet.